Cormorant Asset Management LP 13D and 13G filings for Tarsus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 3:05 pm Sale | 2024-09-30 | 13G | Tarsus Pharmaceuticals, Inc. TARS | Cormorant Asset Management LP | 500,000 1.310% | -1,721,422 (-77.49%) | Filing |
| 2024-02-14 3:04 pm Purchase | 2023-12-31 | 13G | Tarsus Pharmaceuticals, Inc. TARS | Cormorant Asset Management LP | 2,221,422 6.710% | 485,000 (+27.93%) | Filing |
| 2023-02-14 3:04 pm Purchase | 2022-12-31 | 13G | Tarsus Pharmaceuticals, Inc. TARS | Cormorant Asset Management LP | 1,736,422 6.510% | 333,091 (+23.74%) | Filing |
| 2022-02-14 3:01 pm Sale | 2021-12-31 | 13G | Tarsus Pharmaceuticals, Inc. TARS | Cormorant Asset Management LP | 1,403,331 6.790% | -310,938 (-18.14%) | Filing |
| 2021-02-16 3:34 pm Sale | 2020-12-31 | 13G | Tarsus Pharmaceuticals, Inc. TARS | Cormorant Asset Management LP | 1,714,269 8.450% | -249,999 (-12.73%) | Filing |
| 2020-10-30 4:00 pm Purchase | 2020-10-20 | 13G | Tarsus Pharmaceuticals, Inc. TARS | Cormorant Asset Management LP | 1,964,268 9.780% | 1,964,268 (New Position) | Filing |